Marilyn Dix Smith, ISPOR’s Founding Executive Director, Passes Away

Published Oct 23, 2018

Dr Smith Guided and Shaped ISPOR For Nearly 20 Years

Lawrenceville, NJ, USA—October 22, 2018—It is with great sadness that ISPOR—the professional society for health economics and outcomes research, announces the passing of its Founding Executive Director, Marilyn Dix Smith, RPh, PhD. Dr Smith passed away the morning of October 21, 2018. Dr Smith’s vision shaped ISPOR into the leading, global organization for health economics and outcomes research (HEOR). She led the Society through many milestones, including its first scientific conference on HEOR in 1996, the establishment of its regional chapters, the launch of its flagship publication Value in Health, the creation of the Society’s short course program, the founding of its student network, the organization of its global consortia and networks, and the development of its books and many online HEOR resources. For nearly 20 years Dr Marilyn Dix Smith was the guiding force behind ISPOR’s foundation, growth, and direction. She also recognized and greatly valued the contributions of its members and leaders. Upon her retirement in 2014, Dr Smith requested that the Society establish an award to recognize outstanding volunteer leaders for their consistent, broad, and meaningful direction to ISPOR. The Marilyn Dix Smith Leadership Award was established that year in honor of Dr Smith. Prior to founding ISPOR Dr Smith served in a number of executive roles at Lederle Laboratories, including director, managed care pharmacy and director, quality control. Dr Smith received her BS in pharmacy and PhD in pharmaceutical science from Ohio State University. She published a number of scientific articles and delivered many presentations over the years on HEOR-related topics. Dr Smith was also a cofounder of the American Association for Pharmaceutical Scientists, a member of the American Society of Association Executives, and involved in many other pharmacy and healthcare professional organizations. ISPOR offers its condolences to Dr Smith’s husband Dr William F. McGhan who was ISPOR’s first President, to her children, and to her family and many loved ones. Dr Smith will be fondly remembered and sorely missed. For those who would like to pay tribute, post a comment, or tell a story about Dr Smith as the inspiring friend, colleague, and leader that she was, please complete the comment form found here. Comments will be posted to Dr Smith's remembrance page found here.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg    

Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×